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There is considerable interest in plasma homocysteine (tHcy) as a CVD risk factor. Although
the secondary prevention trials published to date have been inconclusive in confirming a benefit
of tHcy-lowering treatment with B-vitamins on CVD events generally, such studies are widely
recognised to have been insufficiently powered to detect a significant effect for the predicted
magnitude of association between tHcy and heart disease risk, and therefore cannot be inter-
preted as evidence that no relationship exists. In fact, a recent meta-analysis of clinical trials
has confirmed that folic acid supplementation reduces the risk of stroke, particularly in indi-
viduals without a history of stroke. Evidence supporting a causal relationship between elevated
tHcy and heart disease also comes from genetic studies. The most important genetic determi-
nant of tHcy in the general population is the common C677T variant in methylenetetra-
hydrofolate reductase (MTHFR) that results in higher tHcy. Individuals with the homozygous
mutant (TT) genotype have a significantly higher (14–21%) risk of heart disease. Plasma tHcy
is very responsive to intervention with the B-vitamins required for its metabolism, in particular
folic acid, and to a lesser extent vitamins B12 and B6. Thus, although primarily aimed at
reducing neural-tube defects, folic acid fortification may have an important role in the primary
prevention of CVD via tHcy lowering. Besides folate, riboflavin is required as a cofactor for
MTHFR and enhanced riboflavin status results in a marked lowering in tHcy specifically in
individuals with the TT genotype, presumably by neutralising the variant form of the enzyme.
About 10% of the UK and Irish populations have the TT genotype. In the present paper the
potential role of folate and related B-vitamins in the primary prevention of CVD and the
implications for nutrition policy are explored.
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Elevated homocysteine as a risk factor for CVD
Evidence from numerous prospective and retrospective
case–control studies has emerged in recent years to link
elevated plasma homocysteine (tHcy) levels with an
increased risk of CVD. Meta-analyses of prospective
studies have predicted that lowering tHcy by 3mmol/l (or a
reduction of 25% based on an average tHcy of 12 mmol/l)
would reduce the risk of heart disease by 11–16% and
stroke by 19–24%(1,2). Although none of the secondary
prevention trials published in more recent years have been
able to confirm the benefit of tHcy-lowering therapy on
CVD events generally(3–5), it should not be assumed that
no relationship exists. It is now generally recognised that
these trials lacked sufficient statistical power to detect an
effect for the predicted magnitude of association between
tHcy and heart disease(6). In support of this viewpoint, a
clear benefit in reducing stroke was shown in one of the
previously mentioned ‘negative’ trials, although this result
was not explicit in the conclusions(4). Moreover, evidence
just published from a meta-analysis of clinical trials in
relation to stroke outcome has confirmed that folic acid
supplementation reduces the risk of stroke by 18% overall,
by 29% in trials with a treatment duration of >36 months
and by 25% in those trials involving individuals without a
history of stroke(7). Such evidence is consistent with the
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findings of a population-based study that has shown that
the temporal decline in stroke-related mortality in the USA
and Canada coincided with the introduction of folic acid
fortification(8). Thus, the case for tHcy as a risk factor in
CVD is stronger for stroke than for heart disease, and
possibly strongest for the primary prevention of stroke.
Another important line of evidence supporting a causal
relationship between elevated tHcy and heart disease
comes from genetic studies. The common C677T variant
in the gene coding for the folate-metabolising enzyme
methylenetetrahydrofolate reductase (MTHFR) is the most
important genetic determinant of tHcy in the general popu-
lation. The homozygous mutant TT genotype for the
MTHFR C677T polymorphism typically affects about
10% of individuals worldwide but can be as high as 26%
(southern Italy) and 32% (Mexico) in some areas(9).
MTHFR is required for the formation of 5-methyltetra-
hydrofolate, which in turn is required to convert homo-
cysteine to methionine. Individuals with the TT genotype
have reduced MTHFR activity, which results in impaired
folate metabolism and elevated tHcy levels(10). Three
recent meta-analyses involving >25 000 cases have exam-
ined the impact on heart disease risk of this genetic variant
and have shown an overall significantly higher (14–21%)
risk of heart disease in individuals with this polymorphism
as compared with those without this polymorphism(2,11,12).
The trend toward increasing risk of disease among indivi-
duals with no (CC genotype), one (CT genotype) or two
copies (TT genotype) of the defective gene is consistent
with the increasing gradient in tHcy typically found among
the three genotypes (as would be expected if there is a
causal relationship between elevated tHcy and risk of dis-
ease). However, analysis of the OR among countries shows
a large geographical variation in the association between
this polymorphism and heart disease risk(11,12).
Homocysteine-lowering with B-vitamins
The B-vitamins folate, vitamin B12 and vitamin B6 are
required for homocysteine metabolism and several studies
have examined their potential to lower tHcy.
Folate
Folate, the focus of much current debate on food for-
tification worldwide, is the major determinant of tHcy. The
first meta-analysis to assess the tHcy-lowering effect of
folic acid has concluded that doses in the range of 0.5 to
5mg/d could lower tHcy by about 20–25%(13). The effect
of doses <0.5mg/d is much less clear but is arguably the
more relevant question for emerging food fortification
policy. Some earlier evidence has suggested that doses in
the range of 0.2–0.4mg/d can achieve a maximum reduc-
tion in tHcy in young healthy populations(14,15), while
another study has shown that doses as high as 0.8mg folic
acid/d are required for maximal lowering of tHcy in those
individuals with established heart disease(16). Similarly, a
meta-analysis of twenty-five randomised trials involving
2596 subjects (both healthy and patient groups) has con-
cluded that a daily dose of 0.8mg/d is required to achieve
a maximal reduction in tHcy, while doses of 0.2 and
0.4mg/d are associated with only 60 and 90% of this
maximal effect respectively(17). However, one limitation
of the latter meta-analysis is treatment duration; of the
twenty-five studies examined the treatment in eighteen was
of £8 weeks duration, six were of 12 weeks duration and
only one was of long-term duration (i.e. 6 months). Some
preliminary evidence suggests that longer treatment dur-
ation may be necessary to allow a complete tHcy-lowering
effect to be observed in response to the lower doses of folic
acid(18). In addition, details on subject compliance were
rarely reported in the original studies that examined the
effect of different doses(17), but this information is critical
to the interpretation of the results because incomplete
compliance by participants may result in an underesti-
mation of the full extent of the tHcy response to a given
dose. Food fortification, unlike supplementation, auto-
matically provides maximal participant compliance; there-
fore, ensuring high subject compliance to the treatments
should be a key aspect of any dose-finding study aimed at
developing food fortification policies for the prevention
of CVD.
Thus, some published reports may have overestimated
the folic acid dose required to achieve maximal tHcy lower-
ing, because of either incomplete or unmonitored subject
compliance or, more importantly, an intervention period
that was too short to observe the full extent of the tHcy
response to lower folic acid doses in the range 0.2–
0.4mg/d. Clearly, the issue as to the lowest dose of folic
acid associated with a maximum reduction in tHcy remains
controversial and requires further investigation, especially
in light of recent reports that highlight potential adverse
effects of overexposure to higher intakes of folic acid(19,20).
Vitamin B12
In addition to folate, the enzyme methionine synthase
involved in the remethylation of homocysteine to methio-
nine requires vitamin B12 as cofactor. Although a number
of studies in healthy populations and in patients have
investigated the effect of various doses of folic acid sup-
plementation in lowering tHcy, few have examined the
independent effects of vitamin B12. In those studies that
have administered low-dose vitamin B12 as a separate
treatment, the response of vitamin B12 biomarkers was the
primary outcome and the tHcy response was measured as
a secondary objective(21,22). Furthermore, the study popu-
lations were selected for mild vitamin B12 deficiency and
were not pretreated with folic acid before vitamin B12
supplementation. Of even greater importance, vitamin B12
was not administered with food, the presence of which is
required to stimulate the normal vitamin B12 absorptive
mechanisms. The tHcy-lowering response observed may
therefore have been confounded by differences in folate
status or an incomplete absorption of the administered
dose.
The reason for the limited number of intervention
studies with vitamin B12 is that this vitamin is generally
considered to be a far-less-effective determinant of tHcy
concentrations compared with folate. However, evidence
from a study of healthy subjects supplemented with
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low-dose folic acid(23) and from studies in the era of
mandatory folic acid fortification of cereal grains in the
USA(24–26) shows that vitamin B12 becomes the main
nutritional determinant of tHcy once folate status is opti-
mised. Furthermore, meta-analyses of intervention studies
that have examined the effect of B-vitamins on tHcy
lowering have shown that including vitamin B12 along
with folate produces an additional one-third (7%) lowering
of tHcy above that achieved with folate alone (typically
25% lowering(13,17)). As the relationship between tHcy and
CVD is graded, any small but significant further decrease
in tHcy concentrations could be predicted to confer an
additional benefit in terms of CVD risk. Although the
results of the randomised clinical trials published so far
are disappointing in that they have failed to show a benefit
of tHcy-lowering therapy on CVD events generally, re-
analysis of data from the negative Vitamin Intervention
for Stroke Prevention trial(3) has shown the importance
of vitamin B12 in relation to tHcy and CVD risk. When
subjects who were considered to receive no benefit from
vitamin therapy were excluded (i.e. patients believed to
be on vitamin B12 supplements and patients with renal
failure), the group receiving the high-dose therapy were
found to have a 21% reduced risk of CVD events com-
pared with the low-dose group(27). Those patients with
higher baseline vitamin B12 levels who received the high-
dose B-vitamin therapy during intervention were shown to
have the best outcome for survival free of a CVD event(27).
Thus, the inclusion of vitamin B12 along with folic acid
may be a more effective therapy for reducing the risk of
CVD via tHcy lowering than folic acid alone. Such a
therapy could be of particular benefit to older adults, as
suboptimal vitamin B12 status (mostly as a result of food-
bound vitamin B12 malabsorption) is highly prevalent
(28)
and CVD is a common cause of morbidity and mortality
in this subgroup of the population. However, further
supplementation studies with vitamin B12 are required to
determine the optimal dose for lowering tHcy.
Vitamin B6
The transulfuration of homocysteine to cysteine by cyst-
athione b-synthase requires vitamin B6 (pyridoxal phos-
phate) as a cofactor, and studies have considered the
potential of vitamin B6 to lower tHcy. Although the litera-
ture generally suggests either that vitamin B6 does not have
a tHcy-lowering effect(13,17) or that it lowers tHcy only in
exceptional circumstances (e.g. in pyridoxine-responsive
homocystinuria or in patients with severe vitamin B6 defi-
ciency), there is some evidence of a small but significant
tHcy response (lowered by 7.5%) to low-dose vitamin
B6
(29). However, the latter intervention was conducted
in healthy older subjects whose status of both folate and
riboflavin was optimised before intervention with vitamin
B6; this study design may explain why a significant tHcy
response was observed in this study but not in other
studies(13,17).
Apart from its role in homocysteine metabolism, vitamin
B6 is also required for the metabolism of n-3 PUFA
(30).
Thus, independently of any tHcy-lowering effect, some
studies have investigated the potential ability of vitamin B6
to suppress some of the underlying mechanisms involved
in the atherosclerotic process such as platelet aggre-
gation(31) and the proliferation of endothelial cells(32). The
findings so far from various studies are inconsistent. The
results from the Nurses’ Health Study of 80 000 women
followed for 14 years have demonstrated that a higher
dietary intake of vitamin B6 (i.e. >3mg/d) is associated
with a decreased risk of heart disease(33). Furthermore,
retrospective and prospective case–control studies have
related low plasma concentrations of vitamin B6-status
indices to increased risk of stroke, peripheral vascular
disease and coronary artery disease(34–37). However, after
adjusting for established CVD risk factors the relationship
between vitamin B6 indices and CVD in some of these
studies was found to be no longer significant(34,38). More-
recent investigations have reported that low vitamin B6
status is related to chronic inflammation(39), which in turn
is known to promote atherosclerosis and the development
of CVD. This finding might suggest that low vitamin B6
status is not an independent risk factor for CVD and stroke
but merely a marker of chronic inflammation. Evidence as
to whether low vitamin B6 status is a causal factor for
CVD can only be provided by controlled intervention
studies. So far, the results of four randomised controlled
trials that included vitamin B6 supplementation (as an
independent treatment or in combination with folic acid
and vitamin B12) for £5 years in patients with pre-existing
CVD have been published, but they have failed to detect
any impact of vitamin B6 on the risk of a recurrent
cardiovascular event(40). However, it is widely acknowl-
edged that these trials were underpowered, and even after
combining them it appears that there is insufficient power
to detect a significant effect on the risk of CVD(40).
Moreover, the doses of vitamin B6 used in these trials were
pharmacological levels (40mg/d), the long-term effects
of which remain unknown. Finally, these trials were con-
ducted in individuals with pre-existing disease and it is
not known whether vitamin B6 would have a role in
the primary prevention of CVD. Carefully-designed and
sufficiently-powered long-term intervention studies exam-
ining the effect on CVD of low doses of vitamin B6 (within
the dietary range) are clearly warranted.
Gene–nutrient interactions
The typical phenotype associated with homozygosity for
the MTHFR C677T polymorphism is elevated tHcy
levels(10). Individuals with the TT genotype are considered
to have increased dietary folate requirements on the basis
that they have lower erythrocyte folate levels compared
with those without this genetic variant(41), and the increase
in tHcy is found to be most marked among those with
lower folate status(42,43).
A fourth, much overlooked, B-vitamin is also involved
in homocysteine metabolism. In addition to folate, ribo-
flavin (in its co-enzymic form FAD) is required as a
cofactor for the MTHFR enzyme. The reduced activity of
the MTHFR 677TT variant of MTHFR has been shown to
result from the inappropriate loss of its FAD cofactor(44).
Observational studies in human subjects that have
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investigated the relationship between riboflavin status and
tHcy in individuals with different MTHFR genotypes have
reported somewhat inconsistent results(45–47). In the USA
an association between riboflavin status and tHcy has
been reported in individuals with the TT genotype in the
Framingham Cohort(45), but this association is confined
only to those with the TT genotype and low folate status;
thus, riboflavin does not seem to be the limiting nutrient.
The two studies conducted in healthy European popu-
lations (Norway and Northern Ireland), however, have both
identified riboflavin as an important determinant of tHcy
among individuals with the TT genotype and have indi-
cated that this effect is not explained by folate(46,47). The
inconsistency between studies is probably explained by the
mandatory fortification of flour with riboflavin in the USA,
which would have the effect of optimising riboflavin status
in the general US population, thereby reducing the extent
to which riboflavin is found to be a limiting nutrient in
determining tHcy levels in individuals with the TT geno-
type. Recent results that show a genotype-specific response
of tHcy to riboflavin supplementation now confirm that
riboflavin is an independent modifier of tHcy in individuals
with the TT genotype. Significant lowering of tHcy in
response to riboflavin supplementation was observed in
healthy individuals with the TT genotype, with levels de-
creasing by as much as 22% overall, and markedly so (by
40%) in those with lower riboflavin status at baseline(48).
No tHcy response to intervention was observed in those
with CC or CT genotypes, despite a significant improve-
ment in riboflavin status in both cases and the pre-selection
of subjects with suboptimal riboflavin status at baseline.
The lack of a tHcy-lowering effect of riboflavin in the
absence of this polymorphism was observed previously, in
an earlier intervention study of healthy elderly individuals
who were also pre-screened for suboptimal riboflavin
status but not for MTHFR genotype(49). The responsive-
ness of tHcy to riboflavin is therefore specific to indivi-
duals with the MTHFR 677TT genotype and represents a
new gene–nutrient interaction.
The inconsistencies in the literature as to whether the
MTHFR C677T polymorphism is associated with a higher
risk of heart disease may also relate to the role of ribo-
flavin. Although meta-analyses have reported an overall
14–21% higher risk of heart disease in individuals with the
TT genotype(2,11,12), analysis of the OR between continents
shows that the excess heart disease risk associated with this
polymorphism is significant in Europe but not in North
America. This geographical variation is generally assumed
to be the result of differences in folate status(11,12), while
riboflavin, the cofactor for MTHFR, is generally over-
looked as a potential modulator of the disease risk as-
sociated with this polymorphism. However, the policy of
mandatory riboflavin fortification has existed for >50 years
in the USA, and given the marked genotype-specific de-
crease in tHcy with riboflavin intervention(48), it is not
unreasonable to suggest that it might also modulate heart
disease risk in this subpopulation with genetic predisposi-
tion to elevated tHcy. Thus, the reported differences
among countries as to whether this polymorphism repres-
ents an increased risk of heart disease may relate not only
to differences in folate as commonly suggested(11,12), but
also to differences in the prevailing riboflavin status. It
could be predicted that individuals with the TT genotype
who also have low riboflavin status would have an excess
risk of heart disease, whereas with optimal riboflavin status
they would not carry the expected risk. Notably, support
for this viewpoint is offered by very recent evidence of
higher blood pressure at baseline and a marked lowering
of both systolic and diastolic blood pressure in response to
riboflavin intervention specifically in patients with the TT
genotype(50).
Implications for nutrition policy
Folate is the major determinant of tHcy. As has been
experienced in the USA since its introduction(51), there is
no doubt that folic acid fortification, if introduced in a
population, would have a major tHcy-lowering effect irre-
spective of genotype. Vitamins B12 and B6 also play key
roles in homocysteine metabolism, with evidence showing
that both vitamins may be important determinants of tHcy,
particularly when folate status has been optimised(23,24,29).
Thus, all three vitamins could arguably be included in any
fortification policy aimed at lowering tHcy in the general
population, with potential benefits in preventing CVD and
possibly stroke in particular(7). Emerging food policy in
different countries should also consider the riboflavin
requirements of individuals homozygous for the common
MTHFR C677T polymorphism. Riboflavin status appears
to be a potent modulator of the expected (high tHcy)
phenotype among individuals with the TT genotype. Of
greater importance, new evidence shows marked lowering
of blood pressure in response to riboflavin intervention
specifically in patients with the TT genotype, which may
or may not be independent of the tHcy-lowering effect
of riboflavin also seen only in the TT genotype(48,50).
Importantly, the fact that these effects of riboflavin are
achievable with a very modest increase in riboflavin intake
(1.6mg/d) suggests that there are important implications
for dietary riboflavin requirements in individuals with this
common genetic variant and for food-fortification policy
aimed at the primary prevention of CVD. In order to cover
the needs of appreciable subgroups (3–32%) of popu-
lations worldwide with this genotype(7) riboflavin may
need to be considered for inclusion together with folic acid
in fortification programmes under discussion.
References
1. Homocysteine Studies Collaboration (2002) Homocysteine
and risk of ischemic heart disease and stroke. JAMA 288,
2015–2022.
2. Wald DS, Law M & Morris JK (2002) Homocysteine and
cardiovascular disease: evidence on causality from a meta-
analysis. Br Med J 325, 1202–1208.
3. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew
LC, Howard VJ, Sides EG, Wang CH & Stampfer M (2004)
Lowering homocysteine in patients with ischemic stroke to
prevent recurrent stroke, myocardial infarction and death: The
Vitamin Intervention for Stroke Prevention (VISP) Random-
ized Controlled Trial. JAMA 291, 565–575.






















Downloaded from https:/www.cambridge.org/core. University of Ulster, on 07 Mar 2017 at 21:15:17, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
4. The Heart Outcomes Prevention Evaluation (HOPE) 2 Inves-
tigators (2006) Homocysteine lowering with folic acid and B
vitamins in vascular disease. N Engl J Med 354, 1567–1577.
5. Bonaa KH, Njølstad I, Ueland PM et al. (2006) Homocysteine
lowering and cardiovascular events after acute myocardial
infarction. N Engl J Med 354, 1629–1632.
6. B-Vitamin Treatment Trialists’ Collaboration (2006)
Homocysteine-lowering trials for prevention of cardiovascular
events: a review of the design and power of the large ran-
domized trials. Am Heart J 151, 282–287.
7. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, Sun N, Liu
L & Xu X (2007) Efficacy of folic acid supplementation in
stroke prevention: a meta-analysis. Lancet 369, 1876–1882.
8. Yang Q, Botto LD, Erickson JD, Berry RJ, Sambell C,
Johansen H & Friedman JM (2006) Improvement in stroke
mortality in Canada and the United States, 1990 to 2002.
Circulation 113, 1335–1343.
9. Wilcken B, Bamforth F, Li Z et al. (2003) Geographical and
ethnic variation of the 677C>T allele of 5,10 methylenetetra-
hydrofolate reductase (MTHFR): findings from over 7000 new-
borns from 16 areas world wide. J Med Genet 40, 619–625.
10. Frosst P, Blom HJ, Milos R et al. (1995) A candidate genetic
risk factor for vascular disease: a common mutation in
methylenetetrahydrofolate reductase. Nat Genet 10, 111–113.
11. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ & Schouten
EG (2003) MTHFR 677C!T polymorphism and risk of
coronary heart disease: a meta-analysis. JAMA 288, 2023–
2031.
12. Lewis SJ, Ebrahim S & Davey Smith G (2005) Meta-analysis
of MTHFR 677C!T polymorphism and coronary heart dis-
ease: does totality of evidence support causal role for homo-
cysteine and preventive potential of folate. Br Med J 331,
1053–1056.
13. Homocysteine Lowering Trialists’ Collaboration (1998)
Lowering blood homocysteine with folic acid based supple-
ments: meta-analysis of randomized trials. Br Med J 316,
894–898.
14. Ward M, McNulty H, McPartlin J, Strain JJ, Weir DG &
Scott JM (1997) Plasma homocysteine, a risk factor for
cardiovascular disease, is lowered by physiological doses of
folic acid. QJM 90, 519–524.
15. Daly S, Mills JL, Molloy AM, Conley M, McPartlin J,
Lee YJ, Young PB, Kirke PN, Weir DG & Scott JM (2002)
Low-dose folic acid lowers plasma homocysteine levels in
women of child-bearing age. QJM 95, 733–740.
16. Wald DS, Bishop L, Wald NJ, Law M, Hennessy E, Weir D,
McPartlin J & Scott J (2001) Randomized trial of folic acid
supplementation and serum homocysteine levels. Arch Intern
Med 161, 695–700.
17. Homocysteine Lowering Trialists’ Collaboration (2005)
Dose-dependant effects of folic acid on blood concentrations
of homocysteine: a meta-analysis of the randomized trials.
Am J Clin Nutr 82, 806–812.
18. Tighe P, Ward M, McNulty H, Finnegan O, Strain JJ, Dunne
A, Molloy AM & Scott JM (2004) Plasma homocysteine
response to folic acid intervention in ischaemic heart disease
patients: implications for food fortification policy. Proc Nut
Soc 63, 51A.
19. Troen AM, Mitchell B, Sorensen B et al. (2006) Unmetab-
olized folic acid in plasma is associated with reduced natural
killer cell cytotoxicity among postmenopausal women. J Nutr
136, 189–194.
20. Cole BF, Baron JA, Sandler RS et al. (2007) Folic acid for
the prevention of colorectal adenomas: a randomized clinical
trial. JAMA 297, 2351–2359.
21. Seal EC, Metz J, Flicker L & Melny J (2002) A randomized,
double-blind, placebo-controlled study of oral vitamin B12
supplementation in older patients with subnormal or border-
line serum vitamin B12 concentrations. J Am Geriatr Soc 50,
146–151.
22. Eussen SJPM, De Groot LCPGM, Clarke R, Schneede J,
Ueland PM, Hoefnagels WHL & van Staveren WA (2005)
Oral cyanocobalamin supplementation in older people with
vitamin B12 deficiency. Arch Intern Med 165, 1167–1172.
23. Quinlivan EP, McPartlin J, McNulty H, Ward M, Strain JJ,
Weir DG & Scott JM (2002) Importance of both folic acid
and vitamin B-12 in reduction of risk of vascular disease.
Lancet 359, 227–228.
24. Liaugaudas G, Jacques PF, Selhub J, Rosenberg IH & Boston
AG (2001) Renal insufficiency, vitamin B-12 status, and
population attributable risk for mild hyperhomocysteinemia
among coronary artery disease patients in the era of folic
acid-fortified cereal grain flour. Arterioscler Thromb Vasc
Biol 21, 849–851.
25. Johnson MA, Hawthorne NA, Brackett WR, Fischer JG,
Gunter EW, Allen RH & Stabler SP (2003) Hyperhomo-
cysteinemia and vitamin B-12 deficiency in elderly using
Title IIIc nutrition services. Am J Clin Nutr 77, 211–220.
26. Robertson J, Lemolo F, Stabler SP, Allen RH & Spence JD
(2005) Vitamin B12, homocysteine and carotid plaque in the
era of folic acid fortification of enriched cereal grain pro-
ducts. Can Med Assoc J 172, 1569–1573.
27. Spence JD, Bang H, Chambless LE & Stampfer MJ (2005)
Vitamin intervention for stroke prevention trial: an efficacy
analysis. Stroke 36, 2404–2409.
28. Wolters M, Strohle A & Hahn A (2004) Cobalamin: a critical
vitamin in the elderly. Prev Med 39, 1256–1266.
29. McKinley MC, McNulty H, McPartlin J, Strain JJ, Pentieva
K, Ward M, Weir DG & Scott JM (2001) Low-dose vitamin
B-6 effectively lowers fasting plasma homocysteine levels in
healthy elderly persons who are folate and riboflavin replete.
Am J Clin Nutr 73, 759–764.
30. Tsuge H, Hotta N & Hayakawa T (2000) Effect of vitamin
B6 on (n-3) polyunsaturated fatty acid metabolism. J Nutr
130, Suppl., 333S–334S.
31. Chang SJ, Chang CN & Chen CW (2002) Occupancy of
glycoprotein IIb/IIIa by B6 vitamers inhibit human platelet
aggregation. J Nutr 132, 3603–3606.
32. Matsubara K, Matsumoto H, Mizuchina Y, Lee JS & Kato N
(2003) Inhibitory effect of pyridoxal 50-phosphate on endo-
thelial cell proliferation, replicative DNA polymerase and
DNA topoisomerase. Int J Mol Med 12, 51–55.
33. Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA,
Manson JE, Hennekens C & Stampfer MJ (1998) Folate and
vitamin B6 from diet and supplements in relation to risk in
coronary heart disease among women. JAMA 279, 359–364.
34. Chasan-Taber L, Selhub J, Rosenberg IH, Malinow MR,
Terry P, Tishler PV, Willett W, Hennekens CH & Stampher
MJ (1996) A prospective study of folate and vitamin B6 and
risk of myocardial infarction in US physicians. J Am Coll
Nutr 15, 136–143.
35. Robinson K, Arheart K, Refsum H et al. (1998) Low circu-
lating folate and vitamin B6 concentrations: risk factors for
stroke, periphery vascular disease, and coronary vascular
disease. European COMAC group. Circulation 97, 437–443.
36. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow
MR, Eckfeldt JH, Hess DL & Davis CE (1998) Prospective
study of coronary heart disease incidence in relation to fast-
ing total homocysteine, related genetic polymorphisms, and
B vitamins: the Atherosclerosis Risk in Communities (ARIC)
study. Circulation 98, 204–210.
37. Kelly PJ, Shih VE, Kistler JP, Barron M, Lee H, Mandell R
& Furie KL (2003) Low vitamin B6 but not homocyst(e)ine
is associated with increased risk of stroke and transient






















Downloaded from https:/www.cambridge.org/core. University of Ulster, on 07 Mar 2017 at 21:15:17, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
ischemic attack in the era of folic acid grain fortification.
Stroke 34, e51–e54.
38. Kelly PJ, Kistler JP, Shih VE, Mandell R, Atassi N, Barron
M, Lee H, Silveira S & Furie KL (2004) Inflammation,
homocysteine and vitamin B6 status after ischemic stroke.
Stroke 35, 12–15.
39. Friso S, Jacques PF, Wilson PWF, Rosenberg IH & Selhub J
(2001) Low circulating vitamin B6 is associated with eleva-
tion of the inflammation marker C-reactive protein indepen-
dently of plasma homocysteine levels. Circulation 103,
2788–2791.
40. Clarke R, Lewington S, Sherliker P & Armitage J (2007)
Effects of B-vitamins on plasma homocysteine concen-
trations and on risk of cardiovascular disease and dementia.
Curr Opin Clin Nutr Metab Care 10, 32–39.
41. Molloy AM, Daly S, Mills JL, Kirke PN, Whitehead AS,
Ramsbottom D, Conley MR, Weir DG & Scott JM
(1997) Thermolabile variant of 5,10-methylenetetrahydro-
folate reductase associated with low red-cell folates: impli-
cations for folate intake recommendations. Lancet 349,
1591–1593.
42. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt
JH, Rosenberg IH, Selhub J & Rozen R (1996) Relation
between folate status, a common mutation in methylene-
tetrahydrofolate reductase, and plasma homocysteine concen-
trations. Circulation 93, 7–9.
43. Brattstro¨m L, Wilcken DEL, Ohrvik J & Brudin L (1998)
Common methylenetetrahydrofolate reductase gene mutation
leads to hyperhomocysteinemia but not to vascular disease –
the result of a meta-analysis. Circulation 98, 2520–2526.
44. Yamada K, Chen Z, Rozen R & Matthews RG (2001) Effects
of common polymorphisms on the properties of recombinant
human methylenetetrahydrofolate reductase. Proc Natl Acad
Sci USA 98, 14853–14858.
45. Jacques PF, Kalmbach R, Bagley PJ, Russo GT, Rogers G,
Wilson PW, Rosenberg IH & Selhub J (2002) The relation-
ship between riboflavin and plasma total homocysteine in the
Framingham Offspring cohort is influenced by folate status
and the C677T transition in the methylenetetrahydrofolate
reductase gene. J Nutr 132, 283–288.
46. Hustad S, Ueland PM, Vollset SE, Zhang Y, Bjorke-Monsen
AL & Schneede J (2000) Riboflavin as a determinant of
plasma total homocysteine: effect modification by the
methylenetetrahydrofolate reductase C677T polymorphism.
Clin Chem 46, 1065–1071.
47. McNulty H, McKinley MC, Wilson B, McPartlin J, Strain JJ,
Weir DG & Scott JM (2002) Impaired functioning of ther-
molabile methylenetetrahydrofolate reductase is dependent
on riboflavin status: implications for riboflavin requirements.
Am J Clin Nutr 76, 436–441.
48. McNulty H, Dowey LC, Strain JJ, Dunne A, Ward M,
Molloy AM, McAnena LB, Hughes JP, Hannon-Fletcher M
& Scott JM (2006) Riboflavin lowers homocysteine in indi-
viduals homozygous for the MTHFR 677C!T polymorph-
ism. Circulation 113, 74–80.
49. McKinley MC, McNulty H, McPartlin J, Strain JJ & Scott
JM (2002) Effect of riboflavin supplementation on plasma
homocysteine in elderly people with low riboflavin status.
Eur J Clin Nutr 56, 850–856.
50. Horigan G, Ward M, McNulty H, Purvis J, Strain JJ & Scott
JM (2007). Riboflavin lowers blood pressure in patients with
premature CVD homozygous for the methylenetetrahydro-
folate reductase (MTHFR) C677T polymorphism. Proc Nut
Soc 66, 95A.
51. Jacques PF, Selhub J, Bostom AG, Wilson PWF & Rosen-
berg IH (1999) The effect of folic acid fortification on
plasma folate and total homocysteine concentrations. N Eng
J Med 340, 1449–1454.






















Downloaded from https:/www.cambridge.org/core. University of Ulster, on 07 Mar 2017 at 21:15:17, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
